Brain Tumor Pathology

, Volume 32, Issue 3, pp 163–168 | Cite as

Involvement of epimutations in meningioma

  • Mario Venza
  • Maria Visalli
  • Concetta Beninati
  • Teresa Catalano
  • Carmelo Biondo
  • Diana Teti
  • Isabella Venza
Review Article
First Online:
Received:
Accepted:

Abstract

Epimutations are heritable and reversible cell markers, which can influence cell function going beyond the effects of DNA mutations. They result from multiple and coordinated mechanisms able to modulate gene expression. Regarding the significance of epigenetics in meningioma, few and somehow contradictory results are available, although promising information has been obtained. Here we highlight the most recent advances about the impact of DNA methylation, histone modifications, and microRNA regulation on meningioma development as well as the interplay between genetic and epigenetic alterations. Data indicate that epigenetics can help to identify novel candidate genes for the management and treatment of meningioma.

Keywords

Meningioma Epigenetics DNA methylation Histone modifications MicroRNA 
This is a preview of subscription content, log in to check access.

Notes

Conflict of interest

The authors report no conflicts of interest related to this study.

References

  1. 1.
    Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415–428CrossRefPubMedGoogle Scholar
  2. 2.
    Ferguson LR, Tatham AL, Lin Z, Denny WA (2011) Epigenetic regulation of gene expression as an anticancer drug target. Curr Cancer Drug Targets 11:199–212CrossRefPubMedGoogle Scholar
  3. 3.
    Venza I, Visalli M, Fortunato C et al (2012) PGE2 induces interleukin-8 derepression in human astrocytoma through coordinated DNA demethylation and histone hyperacetylation. Epigenetics 7:1315–1330PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    Venza M, Visalli M, Biondo C et al (2014) Epigenetic regulation of p14ARF and p16INK4A expression in cutaneous and uveal melanoma. Biochim Biophys Acta 1849:247–256CrossRefPubMedGoogle Scholar
  5. 5.
    Venza M, Visalli M, Biondo C et al (2015) Epigenetic marks responsible for cadmium-induced melanoma cell overgrowth. Toxicol In Vitro 29:242–250CrossRefPubMedGoogle Scholar
  6. 6.
    Venza I, Visalli M, Oteri R, Teti D, Venza M (2014) Class I-specific histone deacetylase inhibitor MS-275 overrides TRAIL-resistance in melanoma cells by downregulating c-FLIP. Int Immunopharmacol 21:439–446CrossRefPubMedGoogle Scholar
  7. 7.
    Venza M, Dell’Aversana C, Visalli M, Altucci L, Teti D, Venza I (2014) Identification of microRNA expression patterns in cutaneous and uveal melanoma cell lines. Tumori 100:e4–e7PubMedGoogle Scholar
  8. 8.
    Venza M, Visalli M, Catalano T et al (2013) Impact of DNA methyltransferases on the epigenetic regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in malignant melanoma. Biochem Biophys Res Commun 441:743–750CrossRefPubMedGoogle Scholar
  9. 9.
    Venza I, Visalli M, Oteri R, Cucinotta M, Teti D, Venza M (2013) Class II-specific histone deacetylase inhibitors MC1568 and MC1575 suppress IL-8 expression in human melanoma cells. Pigment Cell Melanoma Res 26:193–204CrossRefPubMedGoogle Scholar
  10. 10.
    Nebbioso A, Dell’Aversana C, Bugge A et al (2012) HDACs class II-selective inhibition alters nuclear receptor-dependent differentiation. J Mol Endocrinol 45:219–228CrossRefGoogle Scholar
  11. 11.
    Di Bernardo G, Alessio N, Dell’Aversana C et al (2010) Impact of histone deacetylase inhibitors SAHA and MS-275 on DNA repair pathways in human mesenchymal stem cells. J Cell Physiol 225:537–544CrossRefPubMedGoogle Scholar
  12. 12.
    Iwahashi S, Utsunomiya T, Imura S et al (2014) Effects of valproic acid in combination with S-1 on advanced pancreatobiliary tract cancers: clinical study phases I/II. Anticancer Res 34:5187–5191PubMedGoogle Scholar
  13. 13.
    Xia C, Leon-Ferre R, Laux D et al (2014) Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide). Cancer Chemother Pharmacol 74:691–697PubMedCentralCrossRefPubMedGoogle Scholar
  14. 14.
    Venza M, Visalli M, Alafaci C et al (2011) Interleukin-8 overexpression in astrocytomas is induced by prostaglandin E2 and is associated with the transcription factors CCAAT/enhancer-binding protein-β and CCAAT/enhancer-binding homologous protein. Neurosurgery 69:713–721 (discussion 721) CrossRefPubMedGoogle Scholar
  15. 15.
    Caffo M, Barresi V, Caruso G et al (2013) Innovative therapeutic strategies in the treatment of brain metastases. Int J Mol Sci 14:2135–2174PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Caffo M, Caruso G, La Fata G et al (2014) Heavy metals and epigenetic alterations in brain tumors. Curr Genomics 15:457–463PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Maier H, Ofner D, Hittmair A, Kitz K, Budka H (1992) Classic, atypical, and anaplastic meningioma: three histopathological subtypes of clinical relevance. J Neurosurg 77:616–623CrossRefPubMedGoogle Scholar
  18. 18.
    Oya S, Kawai K, Nakatomi H, Saito N (2012) Significance of Simpson grading system in modern meningioma surgery: integration of the grade with MIB-1 labeling index as a key to predict the recurrence of WHO Grade I meningiomas. J Neurosurg 117:121–128CrossRefPubMedGoogle Scholar
  19. 19.
    You JS, Jones PA (2010) Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell 22:9–20CrossRefGoogle Scholar
  20. 20.
    Gao F, Shi L, Russin J et al (2013) DNA methylation in the malignant transformation of meningiomas. PLoS One 8:e54114PubMedCentralCrossRefPubMedGoogle Scholar
  21. 21.
    He S, Pham MH, Pease M et al (2013) A review of epigenetic and gene expression alterations associated with intracranial meningiomas. Neurosurg Focus 35:E5. doi: 10.3171/2013.10.FOCUS13360 CrossRefPubMedGoogle Scholar
  22. 22.
    Kandenwein JA, Park-Simon TW, Schramm J, Simon M (2011) uPA/PAI-1 expression and uPA promoter methylation in meningiomas. J Neurooncol 103:533–539CrossRefPubMedGoogle Scholar
  23. 23.
    Velpula KK, Gogineni VR, Nalla AK, Dinh DH, Rao JS (2013) Radiation-induced hypomethylation triggers urokinase plasminogen activator transcription in meningioma cells. Neoplasia 15:192–203PubMedCentralCrossRefPubMedGoogle Scholar
  24. 24.
    Kishida Y, Natsume A, Kondo Y et al (2012) Epigenetic subclassification of meningiomas based on genome-wide DNA methylation analyses. Carcinogenesis 33:436–441CrossRefPubMedGoogle Scholar
  25. 25.
    Noushmehr H, Weisenberger DJ, Diefes K et al (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17:510–522PubMedCentralCrossRefPubMedGoogle Scholar
  26. 26.
    Vengoechea J, Sloan AE, Chen Y et al (2013) Methylation markers of malignant potential in meningiomas. J Neurosurg 119:899–906CrossRefPubMedGoogle Scholar
  27. 27.
    Di Vinci A, Brigati C, Casciano I et al (2012) HOXA7, 9, and 10 are methylation targets associated with aggressive behavior in meningiomas. Transl Res 160:355–362CrossRefPubMedGoogle Scholar
  28. 28.
    Liu Y, Pang JC, Dong S, Mao B, Poon WS, Ng HK (2005) Aberrant CpG island hypermethylation profile is associated with atypical and anaplastic meningiomas. Hum Pathol 36:416–425CrossRefPubMedGoogle Scholar
  29. 29.
    Lomas J, Amiñoso C, Gonzalez-Gomez P et al (2004) Methylation status of TP73 in meningiomas. Cancer Genet Cytogenet 148:148–151CrossRefPubMedGoogle Scholar
  30. 30.
    Nakane Y, Natsume A, Wakabayashi T et al (2007) Malignant transformation-related genes in meningiomas: allelic loss on 1p36 and methylation status of p73 and RASSF1A. J Neurosurg 107:398–404CrossRefPubMedGoogle Scholar
  31. 31.
    Soussi T (2014) The TP53 gene network in a postgenomic era. Hum Mutat 35:641–642CrossRefPubMedGoogle Scholar
  32. 32.
    Almeida LO, Custódio AC, Pinto GR et al (2009) Polymorphisms and DNA methylation of gene TP53 associated with extra-axial brain tumors. Genet Mol Res 8:8–18CrossRefPubMedGoogle Scholar
  33. 33.
    Jun P, Hong C, Lal A et al (2009) Epigenetic silencing of the kinase tumor suppressor WNK2 is tumor-type and tumor-grade specific. Neuro Oncol 11:414–422PubMedCentralCrossRefPubMedGoogle Scholar
  34. 34.
    Bello MJ, Amiñoso C, Lopez-Marin I et al (2004) DNA methylation of multiple promoter-associated CpG islands in meningiomas: relationship with the allelic status at 1p and 22q. Acta Neuropathol 108:413–421CrossRefPubMedGoogle Scholar
  35. 35.
    Aydemir F, Yurtcu E, Balci TB, Sahin FI, Gulsen S, Altinors N (2012) Identification of promoter region methylation patterns of MGMT, CDKN2A, GSTP1, and THBS1 genes in intracranial meningioma patients. Genet Test Mol Biomark 16:335–340CrossRefGoogle Scholar
  36. 36.
    Linsler S, Kraemer D, Driess C et al (2014) Molecular biological determinations of meningioma progression and recurrence. PLoS One 9:e94987PubMedCentralCrossRefPubMedGoogle Scholar
  37. 37.
    Ando H, Natsume A, Iwami K et al (2013) A hypoxia-inducible factor (HIF)-3α splicing variant, HIF-3α4 impairs angiogenesis in hypervascular malignant meningiomas with epigenetically silenced HIF-3α4. Biochem Biophys Res Commun 433:139–144CrossRefPubMedGoogle Scholar
  38. 38.
    Barski D, Wolter M, Reifenberger G, Riemenschneider MJ (2010) Hypermethylation and transcriptional downregulation of the TIMP3 gene is associated with allelic loss on 22q12.3 and malignancy in meningiomas. Brain Pathol 20:623–631CrossRefPubMedGoogle Scholar
  39. 39.
    Lindner DJ, Wu Y, Haney R et al (2013) Thrombospondin-1 expression in melanoma is blocked by methylation and targeted reversal by 5-Aza-deoxycytidine suppresses angiogenesis. Matrix Biol 32:123–132PubMedCentralCrossRefPubMedGoogle Scholar
  40. 40.
    Cesinaro AM, Sartori G, Migaldi M et al (2012) Prognostic significance of MGMT gene promoter methylation in differently treated metastatic melanomas. Pathology 44:313–317CrossRefPubMedGoogle Scholar
  41. 41.
    Santarius T, Kirsch M, Nikas DC, Imitola J, Black PM (2000) Molecular analysis of alterations of the p18INK4c gene in human meningiomas. Neuropathol Appl Neurobiol 26:67–75CrossRefPubMedGoogle Scholar
  42. 42.
    Costa FF, Colin C, Shinjo SM et al (2005) ADAM23 methylation and expression analysis in brain tumors. Neurosci Lett 380:260–264CrossRefPubMedGoogle Scholar
  43. 43.
    Avci CB, Dodurga Y, Susluer SY et al (2014) Promoter hypermethylation-mediated down-regulation of RUNX3 gene in human brain tumors. Ir J Med Sci 183:259–264CrossRefPubMedGoogle Scholar
  44. 44.
    Lusis EA, Watson MA, Chicoine MR et al (2005) Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma. Cancer Res 65:7121–7126CrossRefPubMedGoogle Scholar
  45. 45.
    Hankins GR, Sasaki T, Lieu AS et al (2008) Identification of the deleted in liver cancer 1 gene, DLC1, as a candidate meningioma tumor suppressor. Neurosurgery 63:771–780 (discussion 780–781) CrossRefPubMedGoogle Scholar
  46. 46.
    Lomas J, Bello MJ, Arjona D et al (2005) Genetic and epigenetic alteration of the NF2 gene in sporadic meningiomas. Genes Chromosomes Cancer 42:314–319CrossRefPubMedGoogle Scholar
  47. 47.
    Hansson CM, Buckley PG, Grigelioniene G et al (2007) Comprehensive genetic and epigenetic analysis of sporadic meningioma for macro-mutations on 22q and micro-mutations within the NF2 locus. BMC Genom 8:16CrossRefGoogle Scholar
  48. 48.
    Zhang X, Gejman R, Mahta A et al (2010) Maternally expressed gene 3, an imprinted noncoding RNA gene, is associated with meningioma pathogenesis and progression. Cancer Res 70:2350–2358PubMedCentralCrossRefPubMedGoogle Scholar
  49. 49.
    Chen MN, Wang P, Zhang J, Zhou BY, Mao Q, Liu YH (2012) Analysis of the role of hMLH1 hypermethylation and microsatellite instability in meningioma progression. Genet Mol Res 11:3933–3941CrossRefPubMedGoogle Scholar
  50. 50.
    Qiu Y, Shabashvili D, Li X, Gopalan PK, Chen M, Zajac-Kaye M (2012) DNA methylation and histone deacetylation: interplay and combined therapy in cancer. InTech, RijekaGoogle Scholar
  51. 51.
    Bush ML, Oblinger J, Brendel V et al (2011) AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas. Neuro Oncol 13:983–999PubMedCentralCrossRefPubMedGoogle Scholar
  52. 52.
    Burns SS, Akhmametyeva EM, Oblinger JL (2013) Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth. Cancer Res 73:792–803PubMedCentralCrossRefPubMedGoogle Scholar
  53. 53.
    Olivera M, Martínez C, Molina JA et al (2006) Increased frequency of rapid acetylator genotypes in patients with brain astrocytoma and meningioma. Acta Neurol Scand 113:322–326CrossRefPubMedGoogle Scholar
  54. 54.
    Breving K, Esquela-Kerscher A (2010) The complexities of microRNA regulation: mirandering around the rules. Int J Biochem Cell Biol 42:1316–1329CrossRefPubMedGoogle Scholar
  55. 55.
    Gattolliat CH, Uguen A, Pesson M et al (2015) MicroRNA and targeted mRNA expression profiling analysis in human colorectal adenomas and adenocarcinomas. Eur J Cancer 51:409–420CrossRefPubMedGoogle Scholar
  56. 56.
    Tsang JY, Ni YB, Ng EK et al (2015) MicroRNAs are differentially deregulated in mammary malignant phyllodes tumor. Histopathology. doi: 10.1111/his.12648 Google Scholar
  57. 57.
    Lu J, Getz G, Miska EA et al (2005) MicroRNA expression profiles classify human cancers. Nature 435:834–838CrossRefPubMedGoogle Scholar
  58. 58.
    Sandoval J, Esteller M (2012) Cancer epigenomics: beyond genomics. Curr Opin Genet Dev 22:50–55CrossRefPubMedGoogle Scholar
  59. 59.
    Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6:857–866CrossRefPubMedGoogle Scholar
  60. 60.
    Kliese N, Gobrecht P, Pachow D et al (2013) miRNA-145 is downregulated in atypical and anaplastic meningiomas and negatively regulates motility and proliferation of meningioma cells. Oncogene 32:4712–4720CrossRefPubMedGoogle Scholar
  61. 61.
    Saydam O, Shen Y, Würdinger T et al (2009) Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway. Mol Cell Biol 29:5923–5940PubMedCentralCrossRefPubMedGoogle Scholar
  62. 62.
    Shi L, Jiang D, Sun G et al (2012) miR-335 promotes cell proliferation by directly targeting Rb1 in meningiomas. J Neurooncol 110:155–162CrossRefPubMedGoogle Scholar
  63. 63.
    Zhi F, Zhou G, Wang S et al (2013) A microRNA expression signature predicts meningioma recurrence. Int J Cancer 132:128–136CrossRefPubMedGoogle Scholar

Copyright information

© The Japan Society of Brain Tumor Pathology 2015

Authors and Affiliations

  • Mario Venza
    • 1
  • Maria Visalli
    • 2
  • Concetta Beninati
    • 3
  • Teresa Catalano
    • 2
  • Carmelo Biondo
    • 3
  • Diana Teti
    • 2
  • Isabella Venza
    • 1
  1. 1.Department of Experimental Specialized Medical and Surgical and Odontostomatology SciencesUniversity of MessinaMessinaItaly
  2. 2.Department of Clinical and Experimental MedicineUniversity of MessinaMessinaItaly
  3. 3.Department of Pediatric, Gynecological, Microbiological and Biomedical SciencesUniversity of MessinaMessinaItaly

Personalised recommendations